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PROLOGUE 
Gastroesophageal reflux disease (GERD) is a pathologic 
condition of injury to the esophagus caused by regurgitation of 
gastric or gastroduodenal contents into the lumen of the 
esophagus(1). Histopathology of the esophageal mucosa may or 
may not be present. Gastroesophageal reflux of acid and gastric 
contents often causes a condition commonly referred to as 
heartburn. This is characterized as a retro-sternal burning 
sensation that radiates to the throat and interscapular region. It 
may be confused, even in the emergency room, with anginal 
pain or the onset of myocardial infarction; therefore its rapid 
diagnosis is important. In many patients GERD should be 
considered a chronic and lifelong illness and maintenance 
therapy is often needed(2). Repeated exposure of the esophagus 
to stomach contents leads to esophagitis. In severe cases, this 
can actually erode esophageal tissue (erosive esophagitis). In 
the last five to seven years several new treatment options for 
GERD have become available. These include antise-cretory 
agents such as the proton pump inhibitors, and new surgical 
techniques that have improved Nissen fundoplication safety and 
efficacy rates(3-4). Clinicians caring for patients with this 
common disorder need to understand the pathology behind 
GERD, its common (and uncommon) clinical manifestations, 
and current treatment options as recommended by the American 
College of Gastroenterology(2). 
EPIDEMIOLOGY 
Gastroesophageal reflux is a common ailment involving 7-10 
percent of the population in the United States (5). An estimated 
15 million physician visits occur yearly in the U.S. for GERD, 
mostly in primary care settings. More than 60 million American 
adults experience GERD and heartburn at least once a month, 
and about 25 million adults suffer daily from heartburn. It is 
estimated that 30-70 percent of patients with GERD have 
esophagitis, with about 10 percent of those patients having 
severe erosive esophagitis (6). Twenty-five percent of pregnant 
women experience daily heartburn, and more than 50 percent 
have occasional distress (5). Recent studies show that GERD in 
infants and children is more common than previously 
recognized and may produce recurrent vomiting, coughing, 
other respiratory problems, or failure to thrive. Many patients 
do not seek physician consultation for symptoms. In fact, over-
the-counter medications are the most common treatments used 
by GERD patients; thus, heartburn is one of the most common 
reasons for pharmacist consultation (7). Prevalence increases 
over age 40, and the disease is much more common in men than 
in non-pregnant women. The majority of patients with GERD 
will require pharmacotherapy for symptom alleviation, but up 
to 46 percent of patients with mild disease are successfully 
managed with self-treatment (2). 
PATHOLOGY 
The lower esophageal sphincter (LES) is an area of high 
intraluminal pressure present near the esophagogastric 
junction. The LES allows food to pass into the stomach and 
prevents food and acidic stomach juices from flowing back 
into the esophagus. Gastroesophageal reflux occurs when the 
LES is weak or relaxes inappropriately, allowing the 
stomach's contents to flow up into the esophagus leading to 
the symptoms of GERD (1). These symptoms may last as 
long as two hours, and are often worse after eating a large 
meal. Transient lower esophageal sphincter relaxations, 
which occur in the absence of peristalsis are responsible for 
the majority of GERD symptoms (8). These relaxations are 
vagally mediated, but the reflex arc that produces them can 
be affected by stimulation of other receptors. The severity of 
GERD depends on LES dysfunction as well as the type and 
amount of fluid brought up from the stomach and the 
neutralizing effect of saliva. The main pathophysiologic 
mechanism in GERD is due to ineffective clearance of 
intraluminal contents and a defective gastroesophageal 
barrier(9). There are two factors that determine defective 
clearance: the first is a lack of normal secondary peristalsis 
to remove the injurious material from the esophagus, and the 
second, the presence of gastro-paresis, or defective gastric 
emptying can lead to a greater than normal volume of 
material in the stomach which increases the risk of reflux. 
The LES is not an anatomical valve but an area of higher 
pressure separating the esophagus from the gastric fundus. 
This zone of high pressure is two to four centimeters long 
and maintains a resting tone of 10-30 mmHg. LES tone 
decreases during swallowing to allow evacuation of material 
but otherwise prevents material passing in either direction. 
When LES pressure is reduced to less than six mmHg, 
regurgitation may occur. 
Other factors are also involved in the pathogenesis of 
GERD. As mentioned above the composition of the refluxed 
material can contribute to the development of GERD. Acid 
and pepsin from the stomach can damage esophageal mucosa 
(l0). Duodenal contents can include bile acids and pancreatic 
enzymes both of which can injure tissue. There are several 
esophageal defense mechanisms which may be impaired in 
GERD. Under normal circumstances gastrointestinal 
peristalsis will clear gastric contents from the esophagus, but 
in some cases of GERD peristaltic dysfunction may play an 
important role (11). Residual acid in the esophagus left 
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Table I. Drugs that can decrease lower esophageal 
sphincter tone 
Calcium channel blockers 
Nitrates 
Theophylline 
Anticholinergics 
Narcotics 
Beta-agonists 
Estrogen and progesterone 
after peristalsis is incrementally neutralized by saliva with each 
swallow. In addition, saliva contains a number of growth factors, 
such as epidermal growth factor, which may provide some 
degree of cytoprotection against acids (12). However conflicting 
evidence exists that either salivary flow or components are 
deficient in patients with GERD. Recently Smoak and associates 
demonstrated that chewing gum (which increases both salivary 
flow rates and bicarbonate concentration) increases esophageal 
pH (pH 6.45 to 7.41, P < 0.001)(13). Thus, the exact role 
salivary dysfunction plays in the pathogenesis of GERD is still 
uncertain. Finally some evidence exists that Helicobacter pylori 
infection may actually be protective against developing GERD, 
although this data needs confirmation (14). 
Tone of the LES may be influenced by a number of 
intrinsic and extrinsic factors. Several of these have been 
associated with exacerbation of GERD symptoms. Direct 
mucosal irritation or decreasing LES tone can occur with 
certain foods (spicy foods, acidic foods, chocolate, onions, 
coffee, and alcohol) and cigarette smoking (2,15). Though high 
fat content meals have been thought to exacerbate GERD, 
recent studies have called this into question (16-18). Increased 
intra-abdominal pressure (i.e., from prolonged coughing) can 
also predispose patients to GERD. Other disease states can also 
play a role in the pathogenesis of GERD. Disorders that delay 
gastric emptying time, such as diabetic gastroparesis, can cause 
GERD symptoms, including dysphagia (19). Finally, some 
drugs decrease LES tone and can exacerbate or even cause 
GERD (Table I)(20). Other drugs, such as non-steroidal anti-
inflammatories, oral potassium supplements, and the 
bisphosphonates can cause direct contact irritation or even 
erosion in some patients (21-22). These agents should be used 
with caution in patients with GERD, or suspected as a causative 
agent in certain presentations. 
GERD sometimes results in serious complications. 
Esophagitis may cause bleeding or ulcers. In addition, a 
narrowing or stricture of the esophagus may occur after long 
term esophagitis. Barrett's esophagus, which is replacement of 
the squamous epithelial lining of the esophagus by columnar-
type epithelium, occurs in a small percentage of patients with 
chronic GERD and esophagitis. This condition is believed to 
be a precursor to esophageal cancer. Patients with Barrett's 
esophagus should be monitored regularly by endoscopy and 
their reflux should be treated aggressively (23). 
CLINICAL PRESENTATION 
The clinical presentations for GERD can vary widely, and 
constellations of symptoms can be generally broken down into 
typical, atypical, and complicated presentations of the disease. 
The hallmark symptom of GERD is usually heartburn, a feeling 
of warmth and pressure/pain that may radiate to the neck. Other 
typical symptoms of GERD include waterbrash (hyper-
salivation), belching, and regurgitation (2). Dysphagia as well 
Table II. Grading system for esophagitis 
Grade 0 = Normal 
Grade 1 = Erythematous mucosa with edema 
Grade 2 = Mild erosions 
Grade 3 = Erosions around entire circumference of esophagus, or 
mild ulcerations 
Grade 4 = Deep ulcerations, strictures, etc 
as unexplained weight loss and hematemesis are often 
considered "alarm" symptoms by clinicians, because their 
presence may indicate serious complications of GERD such as 
stricture, perforation or cancer. Atypical symptoms of GERD 
are less common, but can be more serious. These include 
atypical chest pain, hoarseness, throat tightness, asthma, 
chronic cough, hiccups, recurrent otitis in children, and lingual 
dental erosion. Recent attention has been focused on asthma 
symptoms exacerbated or caused by GERD (24). Asthma 
patients have an increased prevalence of GERD, and 
appropriate treatment with antisecretory agents can improve 
asthma symptoms, but may have little effect on objective 
pulmonary function tests(25). Complicated GERD is marked 
by severe symptoms and usually severe, erosive esophagitis. 
Continual pain, odynophagia, esophageal stricture/spasm, and 
other symptoms may occur in patients with complicated 
GERD. As mentioned above, the most feared complication of 
GERD is Barrett's esophagus. However, new evidence 
suggests that GERD with or without Barrett's esophagus is a 
risk factor for esophageal adenocarcinoma (26). A recent 
retrospective trial found that the risk of esophageal cancer 
increases dramatically in patients with longstanding heartburn 
symptoms. Unfortunately, it is not known whether appropriate 
treatment of GERD will decrease the risk of cancer. 
Diagnosis of GERD is often made solely from clinical 
symptoms (2). Patients who have mild to moderate heartburn 
symptoms often require no further tests, and empiric therapy 
can be initiated. If this fails, or the patient has severe or 
atypical symptoms, other diagnostic measures are indicated. 
Studies that determine the presence of esophageal mucosal 
injury include upper gastrointestinal endoscopy, and air-
contrast barium esophagrams. Endoscopy is more sensitive for 
detecting mild or moderate mucosal injury and allows the 
clinician to objectively classify this injury (Table II). Other 
diagnostic tests such as provocative acid challenges, 
ambulatory pH monitoring, and esophageal manometry are 
less commonly used. These procedures are usually reserved 
for patients with refractory or atypical symptoms, or for 
patients considering antireflux surgery (4). 
TREATMENT 
Therapy is usually graded starting with behavior modification, 
which is considered the cornerstone of therapy. Patients showing 
slight to moderate symptoms (no dysphagia, hoarseness, or 
aspiration) may be given instruction on lifestyle changes such as 
avoidance of tight-fitting garments, reduction or elimination of 
alcohol and tobacco products, avoidance of food which may 
produce symptoms (as described above), and refraining from 
eating 4-6 hours prior to sleep. Weight loss is helpful if the patient 
is overweight and sleeping with the head of the bed elevated 4-6 
inches to decrease nocturnal reflux is also recommended. 
The immediate utility for drug therapy in GERD is the 
rapid relief of the pain and distress of heartburn. However, 
healing of esophagitis and prevention of complications by 
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Table III. American College of Gastroenterology treatment guidelines for GERD 
Severity Symptoms First line Refractory Tx 
Mild <2x/wk Patient Directed PPI or H2RA 
Moderate > 2x/wk or Mild PPI or H2RA PPI or high dose H2RA 
 Esophagitis   
Severe Severe Sx or PPI High Dose PPI or Surgery 
 Moderate or >   
 Esophagitis   
Sx = Symptoms, PPI = Proton pump inhibitor, H2RA = Histamine 2 receptor antagonist. Patient directed therapy = as needed over-the-counter antisecretory agents. 
maintenance of remission is important in long-term treatment. 
Many patients with moderate to severe GERD will require 
long-term, perhaps lifelong therapy(27). Neutralization or 
prevention of gastric acid encroachment on the esophageal 
mucosa in order to prevent or help heal esophagitis is the 
primary approach to therapy. An ideal agent should provide 
both immediate relief of pain and distress while providing 
long-term protection of the esophageal mucosa. None of the 
therapies available today are ideal, but a high degree of 
benefit can be obtained if the patient is compliant with the 
treatment plan. 
The American College of Gastroenterology (ACG) 
released guidelines for the diagnosis and treatment of GERD in 
1995, and these recommendations were updated in 1999(2,28). 
The ACG stratifies disease severity by symptom frequency and 
presence of esophagitis, and suggests therapy based on these 
parameters (Table III). On the whole, mild symptoms of GERD 
can be treated with as needed over-the-counter antacids or his-
tamine-2 receptor antagonists (H2RAs). For mild refractory 
disease, a standard dose H2RA is a reasonable first option. 
More severe disease (usually symptoms greater than two times 
weekly, or patients with documented erosive esophagitis) 
should be investigated by a physician. If GERD is confirmed, 
proton pump inhibitors (PPIs) are rapidly becoming the agents 
of choice (3). PPIs are considerably more effective in relieving 
symptoms and healing esophagitis than H2RAs (2,3,27). 
Controversy exists whether a step up approach (starting with 
OTC medications and lifestyle modifications and moving up to 
PPIs if needed), or a step down (starting with PPIs and moving 
down to H2RAs after a certain period of time) strategy is more 
cost effective. PPIs are effective in healing even Grade 3 and 4 
esophagitis, generally achieving a >90 percent cure rate (29). 
Prokinetic agents such as metoclopramide and cisapride are 
generally considered equal in efficacy to standard dose H2RAs 
for GERD (30). Unfortunately, the former agent is associated 
with many central nervous system and endocrine adverse 
effects, and the latter drug has been essentially withdrawn from 
the US market due to reports of ventricular arrhythmias (31,32). 
Laparoscopic Nissen Fundoplication is an emerging option for 
patients refractory to medical therapy (4). Though it is debated 
which therapy is more efficacious overall, surgery is still 
considered a last resort option in most cases. 
PHARMACOTHERAPY FOR GERD (TABLE IV)  
Antacids 
Antacids act by neutralizing the gastric contents and 
usually contain varying amounts of aluminum, calcium and/or 
magnesium. These agents are effective in treating GERD, but 
large and frequent dosing is often necessary for more severe 
disease (33). Thus, as needed dosing remains the rational niche 
for antacids in GERD. Despite popular belief, actual dosage 
form has little impact on effectiveness. Alginic acid- containing 
antacids such as Gaviscon® form a precipitate viscous layer, or 
raft, which floats on top of the gastric contents to provide a 
mechanical barrier to the esophageal mucosa. Studies indicate 
that these agents are equal or perhaps superior to other antacids 
in treating GERD(34). Adverse effects include constipation or 
diarrhea. In renal failure patients, toxic levels of both 
magnesium and aluminum can accumulate; therefore long term 
use of these agents should be avoided in this population (33). 
These agents can bind to several drug classes including 
quinolones, and tetracyclines. Also, some medications require 
an acid medium in the stomach to be absorbed (e.g., 
ketoconazole, itraconazole, and dapsone). Any drug increasing 
gastric pH can decrease the absorption of these agents. 
Histamine-2 Receptor Antagonists 
Four H2RAs are available in the U.S.: cimetidine, 
ranitidine, nizatidine, and famotidine. H2RAs on the U.S. 
market are generally less expensive than PPIs. Most patients 
tolerate H2RAs well, and these agents are considered safe 
enough to be licensed for over-the-counter use. Of all these 
drugs, cimetidine has a number of unique idiopathic adverse 
effects (including neutropenia, gynecomastia, galactorrhea, 
drug fever, and depression), as well as the most numerous 
clinically significant drug interactions (35). Cimetidine 
actively inhibits the Cytochrome P-450 microsomal enzyme 
system, and has been reported to decrease the clearance of 
several medications. It also blocks the tubular secretion of 
several drugs (e.g., metformin)(36). 
Proton Pump Inhibitors 
As mentioned above, PPIs are superior to H2RAs in treating 
GERD. Two major theories exist to explain this finding. First, 
PPIs block the final common pathway of acid production, 
while H2RAs block only one mediator. Evidence also 
suggests that tolerance to the antisecretory effects of H2RAs 
can occur (37). This tachyphylaxis does not appear to occur 
with PPIs. In either event, many clinicians consider PPIs as 
the drugs of choice for treating all but mild symptoms of 
GERD. Five PPIs are currently on the US market: 
omeprazole, panto-prazole, rabeprazole, lansoprazole, and 
esomeprazole. All are probably equally effective (3). They are 
remarkably well tolerated drugs, with few serious adverse 
effects (38). Drug interactions are rare with these medications, 
however, omeprazole has been reported to increase the 
anticoagulant effect of warfarin(39). PPIs work by inhibiting 
activated proton pumps; thus they are best taken in the 
morning on an empty stomach. Daily activation of remaining 
proton pumps along with de novo synthesis results in a 
"steady state" of about 3-4 days of PPI treatment leading to 
nearly 100 percent suppression of proton pump activity. 
Pharmacokinetic parameters of these agents are similar. 
Clinically relevant differences are few, however,
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Table IV. Comparison of histamine-2 receptor antagonists and proton pump inhibitors 
Agent Dose ADRs Cost Comments 
H2RAs    Must reduce does of all agents in renal 
dysfunction, oral agents have 100% 
bioavailability 
Cimetidine 300mg orally four times 
daily or 800 mg at bedtime 
confusion, dizziness, 
gynecomastia, increased 
LFTs. MANY interactions 
$ Inexpensive. Inhibits CYP-450 enzyme 
system and also tabular secretion of many 
drugs 
Nizatidine 150mg orally twice daily 
increased LFTs 
confusion, dizziness, $$ Fewer interactions compared to cimetidine. 
Confusion and dizziness can occur, 
especially in those with renal dysfunction 
and the elderly 
Ranitidine 150mg orally twice daily 
or 300mg at bedtime 
confusion, dizziness, 
increased LFTs 
$$ As above for nizatidine 
Famotidine 200mg orally twice daily 
or 40mg orally at bedtime 
confusion, dizziness, 
thrombocytopenia 
$$ As above for nizatidine 
Proton Pump Inhibitors    Generally more effective in treating GERD 
than H2RAs. Usually more expensive than 
H2Ras 
Omeprazole 20mg orally daily Headache, diarrhea $$$ Both omeprazole and lansoprazole can be 
compounded into suspensions for use down 
feeding tubes 
Lansoprazole 15 to 30 mg orally daily Headache, diarrhea $$  
Rabeprazole 20 mg orally daily Headache, diarrhea $$$  
Esomeprazole 20 to 40 mg orally daily Headache, diarrhea $$$ S-isomer of omeprazole. Clinical 
superiority to other PPIs remains to be 
determined. Should have similar ADRs/DIs 
to omeprazole 
Pantoprazole 40mg orally or 
intravenously daily 
Headache, diarrhea $$/$$$ Available parenterally 
 
lansoprazole absorption is decreased by about 30 percent with 
food (39). The majority of GERD symptoms are well 
controlled with standard doses of these agents. High doses 
(e.g., lansoprazole 30mg twice daily) may be required in a 
small percentage of patients. Also, a minority of patients may 
suffer from breakthrough nocturnal heartburn symptoms 
despite PPI treatment. In these cases one possible strategy 
may be to use a PPI in the morning and a standard dose H2RA 
at bedtime (40). 
Length of Therapy 
Although the majority of patients with erosive 
esophagitis can be healed with up to eight weeks of PPI 
therapy, a subgroup will require chronic, perhaps lifelong 
treatment (2). Maintenance therapy choices are 
controversial, although in general many patients remain 
symptom-free with the stepdown approach described above 
(41). Again, a subset of patients will require long-term 
treatment with PPIs and/or surgery. This suggests an 
individualized approach to the treatment of GERD is the 
most effective strategy (42). 
CONCLUSION 
GERD is a common and serious disorder. In many patients 
this disease can significantly impact their quality of life (42). 
The risk of malignancy development may be considerable in 
patients with longstanding disease. Lifestyle modification and 
rational pharmacotherapy are the cornerstones of treatment for 
this disorder. The pharmacist can play a crucial role in 
counselling of lifestyle changes, helping patients select over-the- 
counter medications, and physician referral. With proper 
treatment the vast majority of patients with GERD can 
achieve significant or total freedom from symptoms. 
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